Viking Therapeutics Balance Sheet
NASDAQ: VKTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viking Therapeutics financial position
At the end of fiscal 2025, Viking Therapeutics reported total assets of $715.7 million, down 21.2% from a year earlier against total liabilities of $76.7 million. Shareholders' equity stood at $639.1 million, or 89.3% of assets. The company held $165.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.33, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Viking Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 165.81M | 26.68M | 55.52M | 36.63M | 26.37M | 29.12M | 8.38M | 24.78M | 8.99M | 3.08M |
| Short-Term Investments | 539.93M | 875.94M | 306.56M | 118.85M | 175.73M | 219.27M | 267.26M | 276.74M | 11.59M | 10.08M |
| Total Current Assets | 715.60M | 907.22M | 367.23M | 167.04M | 210.53M | 256.10M | 283.50M | 302.13M | 21.85M | 13.97M |
| Total Assets | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M | 256.50M | 284.26M | 302.31M | 22.12M | 14.54M |
| Accounts Payable | 53.25M | 9.81M | 7.51M | 8.53M | 1.44M | 3.99M | 2.43M | 959.00K | 1.53M | 1.20M |
| Total Current Liabilities | 76.67M | 27.41M | 19.14M | 21.95M | 8.78M | 12.13M | 6.78M | 4.55M | 8.66M | 6.48M |
| Total Liabilities | 76.67M | 28.04M | 20.07M | 23.21M | 8.78M | 12.16M | 7.14M | 4.56M | 8.66M | 6.49M |
| Shareholders' Equity | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M | 244.34M | 277.12M | 297.75M | 13.46M | 8.04M |
| Retained Earnings | -847.55M | -487.91M | -377.94M | -292.05M | -223.18M | -168.19M | -128.70M | -102.92M | -80.86M | -60.28M |
| Net Cash (Debt) | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M | 248.39M | 275.64M | 301.52M | 20.57M | 13.15M |
| Shares Outstanding | 114.79M | 111.57M | 100.11M | 78.26M | 78.25M | 73.22M | 72.41M | 71.74M | 35.82M | 20.82M |
This table shows 10 annual periods of Viking Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 11 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow VKTX's reporting calendar. What is a balance sheet?